BGB 26808
Alternative Names: BGB-26808Latest Information Update: 28 Oct 2026
At a glance
- Originator BeiGene
- Developer BeOne Medicines
- Class Antineoplastics
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Oct 2026 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in Australia (PO, Tablet)
- 28 Oct 2026 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in China (PO, Tablet)
- 28 Oct 2026 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in New Zealand (PO, Tablet)